000278784 001__ 278784
000278784 005__ 20250604100729.0
000278784 0247_ $$2doi$$a10.1212/WNL.0000000000213705
000278784 0247_ $$2pmid$$apmid:40373242
000278784 0247_ $$2ISSN$$a0028-3878
000278784 0247_ $$2ISSN$$a1526-632X
000278784 037__ $$aDZNE-2025-00620
000278784 041__ $$aEnglish
000278784 082__ $$a610
000278784 1001_ $$00000-0002-5139-6848$$aNitsch, Louisa$$b0
000278784 245__ $$aFactors Associated With Relapse in Patients With Neurosarcoidosis.
000278784 260__ $$aPhiladelphia, Pa.$$bWolters Kluwer$$c2025
000278784 3367_ $$2DRIVER$$aarticle
000278784 3367_ $$2DataCite$$aOutput Types/Journal article
000278784 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1748938269_19908
000278784 3367_ $$2BibTeX$$aARTICLE
000278784 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000278784 3367_ $$00$$2EndNote$$aJournal Article
000278784 520__ $$aFive to 10 percent of patients with sarcoidosis show involvement of the nervous system. Given the serious nature of neurosarcoidosis and the high risk of irreversible neurologic damage, rapid diagnosis, accurate prognostication, and individualized treatment are crucial. The aim of this study was to identify factors associated with relapses in neurosarcoidosis.In this multicenter retrospective cohort study, patients diagnosed with possible, probable, or definite neurosarcoidosis between January 1, 2010, and June 30, 2024, at 6 tertiary neuroimmunology centers across Europe were included. Patients were identified from the respective hospital-based databases by the participating centers. Clinical presentation, imaging results, CSF analysis, and immunosuppressive therapies were evaluated. Predictors of relapse, defined as clinical relapse or progression, or new MRI lesions on follow-up ≥2 months after initial manifestation, were analyzed with log-rank tests and Cox regression models, and therapeutic strategies in clinical practice were assessed. The association between identified risk factors (RFs) and therapeutic strategies was explored.A total of 174 patients with neurosarcoidosis were included with a median follow-up of 24 months (interquartile range 12-48.8). The mean age was 48.1 years, and 57.5% were female. CNS parenchymal lesions including encephalitis, myelitis, and optic neuritis (hazard ratio [HR] 2.3, 95% CI 1.3-4.2); CSF-specific oligoclonal bands (OCBs) (HR 2.1, 95% CI 1.3-3.6); CSF glucose <40 mg/dL (HR 2, 95% CI 1.1-3.4); and CSF protein ≥1,000 mg/dL (HR 2.1, 95% CI 1.3-3.5) were identified as RFs of relapse. Patients with 3-4 RFs had a median relapse-free survival of 12 months (95% CI 4.3-19.7), compared with 36 months (95% CI 24.3-47.7) in patients with 1-2 RFs and 120 months (95% CI 2.1-237.9) in patients without RFs (p < 0.01). The likelihood of treatment escalation increased with the number of RFs, from 14.3% in patients without RFs to 28.2% and 50% in patients with 1-2 or 3-4 RFs, respectively (p < 0.01).The identification of specific RFs, including parenchymal lesions, OCBs, CSF glucose <40 mg/dL, and CSF protein ≥1,000 mg/dL, enables better prognostication and might inform individualized treatment approaches. Patients with multiple RFs are at greater risk of relapse, possibly suggesting the need for more aggressive therapies.
000278784 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000278784 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000278784 650_7 $$2NLM Chemicals$$aImmunosuppressive Agents
000278784 650_2 $$2MeSH$$aHumans
000278784 650_2 $$2MeSH$$aSarcoidosis: cerebrospinal fluid
000278784 650_2 $$2MeSH$$aSarcoidosis: diagnostic imaging
000278784 650_2 $$2MeSH$$aSarcoidosis: epidemiology
000278784 650_2 $$2MeSH$$aSarcoidosis: drug therapy
000278784 650_2 $$2MeSH$$aFemale
000278784 650_2 $$2MeSH$$aMale
000278784 650_2 $$2MeSH$$aMiddle Aged
000278784 650_2 $$2MeSH$$aCentral Nervous System Diseases: cerebrospinal fluid
000278784 650_2 $$2MeSH$$aCentral Nervous System Diseases: diagnostic imaging
000278784 650_2 $$2MeSH$$aCentral Nervous System Diseases: epidemiology
000278784 650_2 $$2MeSH$$aCentral Nervous System Diseases: drug therapy
000278784 650_2 $$2MeSH$$aCentral Nervous System Diseases: diagnosis
000278784 650_2 $$2MeSH$$aAdult
000278784 650_2 $$2MeSH$$aRetrospective Studies
000278784 650_2 $$2MeSH$$aRecurrence
000278784 650_2 $$2MeSH$$aRisk Factors
000278784 650_2 $$2MeSH$$aMagnetic Resonance Imaging
000278784 650_2 $$2MeSH$$aCohort Studies
000278784 650_2 $$2MeSH$$aDisease Progression
000278784 650_2 $$2MeSH$$aImmunosuppressive Agents: therapeutic use
000278784 7001_ $$aSkowasch, Dirk$$b1
000278784 7001_ $$00000-0001-5757-6500$$aCourtin, Edouard$$b2
000278784 7001_ $$aDuffau, Pierre$$b3
000278784 7001_ $$00000-0002-9768-5143$$aOtto, Carolin$$b4
000278784 7001_ $$00000-0003-1962-6014$$aRuprecht, Klemens$$b5
000278784 7001_ $$00000-0003-3734-1055$$aDambietz, Christine$$b6
000278784 7001_ $$00000-0002-9568-2790$$aHeming, Michael$$b7
000278784 7001_ $$00000-0002-4341-4719$$aMeyer Zu Hörste, Gerd$$b8
000278784 7001_ $$aByg, Keld-Erik$$b9
000278784 7001_ $$0P:(DE-2719)9000373$$aKindler, Christine$$b10$$udzne
000278784 7001_ $$aGutzwiller, Julia$$b11
000278784 7001_ $$00009-0001-4129-1276$$aPretzsch, Roxanne$$b12
000278784 7001_ $$0P:(DE-2719)9003515$$aPröbstel, Anne-Katrin$$b13$$udzne
000278784 7001_ $$aWeller, Johannes M$$b14
000278784 7001_ $$00000-0003-1964-0078$$aZimmermann, Julian$$b15
000278784 773__ $$0PERI:(DE-600)1491874-2$$a10.1212/WNL.0000000000213705$$gVol. 104, no. 11, p. e213705$$n11$$pe213705$$tNeurology$$v104$$x0028-3878$$y2025
000278784 909CO $$ooai:pub.dzne.de:278784$$pVDB
000278784 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000373$$aExternal Institute$$b10$$kExtern
000278784 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003515$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b13$$kDZNE
000278784 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000278784 9141_ $$y2025
000278784 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz$$d2025-01-02$$wger
000278784 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROLOGY : 2022$$d2025-01-02
000278784 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-02
000278784 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-02
000278784 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-02
000278784 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-02
000278784 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-02
000278784 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-02
000278784 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-02
000278784 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-02
000278784 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-02
000278784 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-02
000278784 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEUROLOGY : 2022$$d2025-01-02
000278784 9201_ $$0I:(DE-2719)1013045$$kAG Pröbstel$$lClinical Neurology and Neuroimmunology$$x0
000278784 980__ $$ajournal
000278784 980__ $$aVDB
000278784 980__ $$aI:(DE-2719)1013045
000278784 980__ $$aUNRESTRICTED